(Total Views: 303)
Posted On: 12/28/2020 12:07:33 PM
Post# of 63
Short term catalysts abound from top line results for the MAT 9001's second head to head trial vs. Vascepa in 1Q 21, to the DMSC approval for next cohort progression for the MAT 2203 (LNC version of amphotericin b) Phase 2 trial for cryptococcal meningitis in 2Q 21. In addition, the MF Foundation has funded a trial for MAT 2501 (LNC version of amikacin) that should commence soon. Five big pharmaceutical companies, who have entered into collaborations with MTNB show confidence in the company, and its LNC platform.
As for funds, the company has cash on hand sufficient to fund operations through mid-2023. As such, no raise will be needed before major milestones are achieved.
As for funds, the company has cash on hand sufficient to fund operations through mid-2023. As such, no raise will be needed before major milestones are achieved.
(1)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
Scroll down for more posts ▼
